arrow
K

Keith T. Flaherty

Harvard Medical School
H指数:146
被引数:12.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance

多模态血液蛋白质组学分析揭示了免疫治疗耐药机制的见解

2026-06-240
OA
Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

撤稿说明:sFRP2在衰老微环境中驱动黑色素瘤转移和疗法抵抗

Nature
IF48.5
2025-10-290
OAAI
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants

通过靶向CD38克服人类肿瘤移植组织对免疫治疗的抵抗

2025-06-270
OAAI
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

Monson, K.R.; Ferguson, R.; Handzlik, J.E.; Morales, L.; Xiong, J.; Chat, V.; Dagayev, S.; Khodadadi-Jamayran, A.; Simpson, D.; Kazlow, E.; 等. 继承的线粒体遗传学作为预测黑色素瘤免疫检查点抑制疗效的指标。Nat. Med. 2025, 31, 2385–2396. [Google Scholar] [CrossRef]

2025-06-050
OAAI
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis

POLARIS研究的简明语言摘要:一项针对BRAF V600突变黑色素瘤脑转移患者,评估encorafenib联合binimetinib不同剂量的研究

2025-05-260
OA
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

精准肿瘤学中耐药性解码模型:胆管癌对FGFR抑制剂的获得性耐药

2024-12-011
OAAI
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after de fi nitive surgery: a multicenter, retrospective cohort study (vol 65, 102290, 2023)

Dabrafenib联合曲美替尼与anti-PD-1单药治疗BRAF V600-mutant III期黑色素瘤术后的辅助治疗: 一项多中心,回顾性队列研究 (第65卷,102290,2023)

2024-05-010
OAAI
Analysis of biomarker and outcomes data: 7-year update from COLUMBUS
2024-03-220
PRE
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis

POLARIS: 一项2期试验,评估BRAF V600-mutant黑色素瘤脑转移患者的高剂量和标准剂量方案

2024-03-181
OAAI
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Dabrafenib联合曲美替尼与anti-PD-1单药治疗BRAF V600-mutant III期黑色素瘤确定性手术后的辅助治疗: 一项多中心,回顾性队列研究

2023-11-017
OAAI